CeGaT specializes in genetic diagnostics and research solutions, focusing on identifying the genetic causes of rare diseases and supporting oncologists in finding optimal therapy options. Their core technology is Next-Generation Sequencing (NGS), which they provide in a high-throughput format. This technology enables comprehensive genetic analyses, including whole exome and RNA sequencing, epigenomics, microbiome analysis, and translational oncology. CeGaT is committed to maintaining high-quality standards, as evidenced by their accreditations, including CAP/CLIA and ISO certifications, ensuring compliance with international regulations.

In addition to their diagnostic services, CeGaT offers extensive support for clinical studies and pharmaceutical research. Their Research & Pharma Solutions division collaborates closely with researchers and pharmaceutical companies, providing tailored sequencing strategies and project management from planning to results. The company emphasizes teamwork and flexibility, allowing them to adapt to the specific needs of their clients while delivering reliable data for research purposes. Their commitment to innovation and quality has made them a trusted partner in the genomics field, as reflected in positive testimonials from various collaborators.

Germany

We are a world leader in gene analyses for a wide range of medical, research and pharmaceutical applications. Since 2009, we have been helping doctors and patients find the genetic causes of rare diseases. We provide researchers and pharmaceutical companies with genetic analysis for clinical trials and medical innovation. We help oncologists and cancer patients find the best therapy option. We continue to drive science forward with our own insights.

You can find our imprint under the following link: https://www.cegat.de/en/disclaimer/
Sie finden unser Impressum unter folgendem Link: https://www.cegat.de/impressum/

CeGat

Company Details